← Back to Search

Cancer Drug

Balixafortide for Breast Cancer (FORTRESS Trial)

Phase 3
Waitlist Available
Led By Peter A Kaufman, MD
Research Sponsored by Spexis AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the investigator monitored the patient for os status every 6 months (or more frequently) until: death, the patient withdrew consent to follow-up for survival, or until the patient was lost to follow-up (whichever occurred first).
Awards & highlights

FORTRESS Trial Summary

This study is evaluating whether a drug called balixafortide can be used to treat breast cancer.

Eligible Conditions
  • Breast Cancer

FORTRESS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the investigator monitored the patient for os status every 6 months (or more frequently) until: death, the patient withdrew consent to follow-up for survival, or until the patient was lost to follow-up (whichever occurred first).
This trial's timeline: 3 weeks for screening, Varies for treatment, and the investigator monitored the patient for os status every 6 months (or more frequently) until: death, the patient withdrew consent to follow-up for survival, or until the patient was lost to follow-up (whichever occurred first). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (2nd Line+ Population)
Progression Free Survival (3rd Line+ Population)
Secondary outcome measures
Overall Survival (3rd Line+ Population)

FORTRESS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Balixafortide + EribulinExperimental Treatment2 Interventions
Group II: EribulinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eribulin
FDA approved

Find a Location

Who is running the clinical trial?

Spexis AGLead Sponsor
Polyphor Ltd.Lead Sponsor
11 Previous Clinical Trials
410 Total Patients Enrolled
François Ringeisen, MDStudy DirectorPolyphor Ltd.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
2019. "Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03786094.
~74 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top